Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOND-4: Irinotecan and Cetuximab +/- Bevacizumab and Sintilimab in mCRC
NCT07722754Phase 2Recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Jul 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, bevacizumab in colorectal cancer (CRC), sponsored by Guangdong Provincial People's Hospital. Started Jul 2026; status: recruiting.
02
Drugs
sintilimabbevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07722754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07722754.